Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Ovarian Neoplasms 3Neoplasm Metastasis 3Carcinoma 3Fallopian Tube Neoplasms 2Sarcoma 1Renal Insufficiency 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Kidney Neoplasms 1Kidney Diseases 1Congenital Abnormalities 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced Solid Tumors 1

Interventions

trifluridine tipiracil drug combination 1trebananib 1avelumab 1atezolizumab 1Sunitinib 1Paclitaxel 1Oxaliplatin 1Kidney Transplantation 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Kidney Diseases × trebananib × Clear all
NCT01331941 2017-11-06

A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function

Amgen

Phase 1 Completed
35 enrolled
Genitourinary

Kidney Diseases, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡